Crinetics Pharmaceuticals, Inc.
CRNX
$35.70
-$0.35-0.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 5.59% | -12.50% | -19.49% | -20.07% | -4.90% |
| Total Depreciation and Amortization | -1.78% | 5.53% | 3.68% | 17.39% | 2.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.05% | -10.66% | 31.24% | 9.67% | 0.35% |
| Change in Net Operating Assets | 720.20% | -122.64% | 169.23% | -280.72% | -16.40% |
| Cash from Operations | 16.09% | -28.97% | 2.94% | -32.27% | -6.44% |
| Capital Expenditure | 46.93% | 73.05% | -158.43% | -20.41% | -94.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -65.25% | 302.56% | 148.58% | 84.34% | -2,660.50% |
| Cash from Investing | -65.35% | 334.24% | 144.15% | 84.14% | -2,731.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 744.20% | -56.29% | 59.00% | -99.20% | 844.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 164.73% |
| Cash from Financing | 744.20% | -56.29% | 59.00% | -99.20% | 870.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -117.25% | 239.99% | 75.97% | -222.39% | -449.00% |